Last updated: February 2025

Peptide sellers on Shopify UK face account freezes, lengthy underwriting reviews, and high chargeback exposure from card processors. Here's why it happens and how Pay by Bank via Fena provides a compliant, lower-friction alternative.

The payment problem peptide merchants know well

Selling peptides legally in the UK is entirely possible. Getting a payment processor to support you while doing it is another matter.

Card payment networks apply category-level risk classifications that frequently catch peptide sellers — regardless of whether their specific products are compliant, properly labelled, and sold responsibly. The result is a landscape where merchants who have done everything right still face frozen accounts, rejected applications, elevated fees, and the persistent uncertainty of not knowing whether their payment processing will still be working next month.

This guide covers why the payment processing challenge exists for UK peptide sellers, what the most damaging friction points are in practice, how consumer payment preferences are shifting in ways that matter for this market, and how Pay by Bank via Fena provides a route around the structural problems that card-based processing creates.

Quick summary

• Peptide sellers are classified as high-risk by card networks and many payment processors due to regulatory complexity around the category, even when specific products are entirely legal and compliant

• The practical consequences are account freezes, elevated fees, extended underwriting timelines, and the ongoing risk of sudden account termination

• Chargebacks are particularly damaging in this category — often arising from product misunderstanding rather than fraud — and card processors respond to elevated dispute rates by tightening terms further

• UK buyers in this market increasingly prioritise privacy, security, and bank-authenticated payment over card-based options

• Pay by Bank via Fena bypasses card network classification entirely — eligibility is based on legal operation in the UK, not on card category policy — while providing FCA-regulated, compliant payment infrastructure with no chargeback exposure

Why peptide sellers are classified as high risk

The high-risk classification that follows peptide merchants through the payment landscape isn't based on an assessment of any individual business. It's a categorical decision made by card networks and processors at the product category level.

The reasoning from the card network's perspective involves several factors. Peptides occupy regulatory territory that overlaps with research compounds, pharmaceutical precursors, and controlled substances in other jurisdictions — even where specific products are legal in the UK. The category has historically seen higher chargeback rates than typical ecommerce, partly driven by consumer misunderstanding of product labelling and intended use. And the reputational risk for a payment processor of supporting a category that attracts regulatory scrutiny is treated as a reason for caution regardless of individual merchant quality.

For compliant UK peptide merchants, this creates a genuine injustice: being treated as though they share the risk profile of non-compliant sellers simply because they sell in the same category. The payment infrastructure doesn't distinguish between a well-run, fully compliant peptide business and one operating at the margins of legality. Both get the same category flag.

The three most damaging friction points

Account freezes and rejections.

The most acute version of the high-risk problem is the sudden freeze or termination. Merchants who have established card processing relationships — sometimes after months of onboarding — face accounts suspended without detailed explanation during routine risk reviews. In-flight orders can be affected. Pending settlements can be held. The operational disruption is immediate and severe, and rebuilding with a new processor often means starting the underwriting process again.

The unpredictability of this risk is part of what makes it so difficult to manage. A merchant can have a stable processing relationship for twelve months and face termination when a risk review coincides with a volume spike, a chargeback ratio that ticked above a threshold, or a change in the processor's category policy.

Underwriting complexity and delay.

For peptide merchants who do find processors willing to onboard them, the underwriting process is substantially more demanding than standard ecommerce. Certificates of analysis for each product, supplier verification documentation, clear intended use statements, business registration evidence, and sometimes personal financial information are all standard requirements.

Each documentation request adds time. Each review stage adds delay before the merchant can begin taking payments. For a new business or a merchant who has just lost a processing relationship, this delay has direct cash flow consequences. And after all of it, approval is not guaranteed.

Chargebacks and their compounding effects.

Card chargebacks are problematic for any merchant, but they're particularly damaging in the peptide category. Disputes often arise not from fraud but from customer confusion — about what the product does, how it should be used, what "research use only" labelling means, or simply from a purchase that wasn't what the customer expected. These are often legitimate sales that get disputed through the chargeback mechanism rather than resolved through customer service.

The damage compounds quickly. Each chargeback triggers a fee. A rising chargeback ratio prompts the processor to scrutinise the account more closely, potentially raising fees, requiring rolling reserves, or initiating a review that leads to account termination. The cost of managing chargebacks — in fees, in staff time, in the risk of account action — is disproportionate to the actual dispute amounts involved.

How consumer payment preferences are shifting in this market

Understanding what peptide buyers in the UK want from a payment experience matters independently of the merchant's processing challenges — because aligning with consumer preferences is also a conversion lever.

Privacy and data minimisation.

Buyers of research compounds and specialist health products increasingly prefer payment methods that minimise data exposure. Entering card details on a merchant website they're unfamiliar with creates a risk calculation that not all customers resolve in favour of completing the purchase. Payment methods that don't require sharing card credentials with the merchant address this concern directly.

Pay by Bank is particularly well-suited here. The customer authenticates within their own banking environment — no card number is shared with the merchant, no credential is stored in the merchant's systems, and the only information that passes back to the checkout is a payment confirmation. For privacy-conscious buyers in a specialist market, this is a meaningful advantage over card entry.

Bank-authenticated security.

Related to privacy but distinct from it: buyers who are cautious about online payment security are increasingly comfortable with bank-authenticated payment flows. Authenticating a payment through the same banking app they use for everyday banking feels more controlled and more transparent than entering card details on an unfamiliar checkout page. As open banking familiarity grows among UK consumers — over 11 million use open banking services monthly — this preference is becoming more common rather than more niche.

Mobile-first, low-friction checkout.

The majority of UK ecommerce traffic is now on mobile, and the peptide market is no different. Mobile card entry is friction-heavy — finding the card, typing sixteen digits accurately on a small keyboard, completing 3DS verification. Payment flows that work natively in a mobile banking environment, using biometric confirmation the customer already uses daily, convert better on mobile than manual card entry. Pay by Bank via Fena integrates with Shopify's mobile checkout cleanly, with a redirect flow that is fast, familiar, and returns the customer to confirmation quickly.

Why Pay by Bank addresses the processing challenge structurally

The core insight for peptide merchants is that Pay by Bank via Fena bypasses card networks entirely — which means card network risk classification policies don't apply.

Card processor restrictions on peptide merchants exist because card networks have made categorical decisions about which product types they're willing to process. Pay by Bank uses UK open banking payment rails rather than card network infrastructure. There is no Visa or Mastercard in the payment flow. There is no card network acceptable use policy to fall foul of. Eligibility is based on whether the merchant operates legally in the UK and meets Fena's compliance requirements — not on a card category policy applied to the entire peptide sector regardless of individual merchant quality.

FCA-regulated infrastructure.

Fena is FCA-authorised to provide open banking payment services. The payment infrastructure is the same regulated open banking framework that the major UK banks are required to support. For peptide merchants who need to demonstrate that their payment processing meets compliance standards — whether to suppliers, accountants, or in response to any regulatory enquiry — FCA-regulated infrastructure provides a clear and credible foundation.

No chargebacks.

Pay by Bank transactions don't go through card networks, so card chargeback mechanisms don't apply. The dispute process that generates fees, triggers risk reviews, and contributes to account termination risk for card-based peptide merchants is simply not a feature of the Pay by Bank model for those transactions. Disputes between merchants and customers are handled directly, without card network involvement, fees, or timelines.

Real-time settlement.

Pay by Bank via Fena settles same-day or instantly rather than on the multi-day card settlement cycle. For merchants who have experienced holds on card settlements during risk reviews — where earned revenue becomes temporarily inaccessible — this is a material operational improvement. Revenue arrives when it's earned.

Compliance tooling built in.

Fena's integration includes KYC verification, age verification where required, and fraud prevention capabilities. These are the tools compliant peptide merchants need to demonstrate responsible selling — and they're part of the payment flow rather than requiring separate configuration and management.

What changes and what doesn't

Pay by Bank via Fena changes the processing infrastructure and removes the card-based friction points. It doesn't change the merchant's obligations.

Peptide merchants still need to comply with MHRA guidelines, ensure products are accurately labelled, include appropriate intended use statements, and meet any age verification requirements that apply to their specific product range. Responsible selling remains the merchant's responsibility — the payment infrastructure supports it but doesn't substitute for it.

What changes is that compliant merchants are no longer penalised by infrastructure designed for a different risk profile. A well-run peptide business that has done the regulatory work has a payment option that recognises the difference between its operation and the worst-case scenarios card processors are trying to avoid.

For merchants currently using card processing and experiencing the friction described above — or concerned about its future occurrence — Pay by Bank via Fena adds a more stable, lower-cost payment option alongside existing methods rather than requiring a complete switch. Customers who prefer cards can continue to use them. Customers who prefer Pay by Bank — or who encounter a card decline and need an alternative — have a reliable path to completing the purchase.

Frequently asked questions

Why are peptide sellers classified as high risk for payment processing?

Card networks apply category-level risk classifications to peptides based on regulatory complexity around the category, historical chargeback rates, and the overlap between peptide products and regulated or restricted compounds in other jurisdictions. This classification applies regardless of whether a specific merchant is operating compliantly — it's a categorical decision rather than an individual assessment.

What documents does a peptide merchant typically need for card processor underwriting?

Standard requirements include certificates of analysis for products, supplier verification documentation, clear product descriptions with intended use statements, business registration documents, and sometimes personal financial information. Requirements vary by processor, and the review period can take days to weeks before approval or rejection.

Can UK peptide merchants use Pay by Bank instead of card processors?

Yes. Pay by Bank via Fena is available to UK Shopify merchants selling peptides legally, and bypasses card network classification entirely because it uses open banking payment rails rather than card infrastructure. Eligibility is based on legal operation in the UK and meeting Fena's compliance requirements — not on card category policies.

How does Pay by Bank eliminate chargeback risk for peptide sellers?

Pay by Bank transactions are bank-authenticated and settle directly between accounts. They don't go through card networks, which means card chargeback mechanisms don't apply. There are no chargeback fees, no dispute response deadlines, and no card network monitoring thresholds on Pay by Bank volume. Disputes are handled directly between merchant and customer without card network involvement.

Do peptide buyers in the UK prefer bank-based payment?

A growing segment does, particularly buyers who are privacy-conscious about sharing card details with specialist merchants and those who prefer bank-authenticated security over card credential entry. As open banking familiarity grows among UK consumers, this preference is becoming more common. Pay by Bank also removes the card data exposure concern for buyers who prefer not to store card details with multiple merchants.

Is Pay by Bank via Fena compliant for regulated product categories?

Yes. Fena is FCA-authorised to provide open banking payment services and operates under UK financial regulation. The integration includes KYC verification, age verification where required, and fraud prevention capabilities. For peptide merchants who need to demonstrate that their payment processing meets compliance standards, FCA-regulated infrastructure provides a clear and verifiable foundation.

Does using Pay by Bank affect the customer's checkout experience?

Minimally. Customers selecting Pay by Bank choose their bank from a list of major UK banks, authenticate the payment within their banking app using existing credentials, and are returned to the order confirmation page. For mobile users particularly, this flow is often faster and less friction-heavy than card entry with 3DS verification. It appears as an additional option alongside any existing payment methods rather than replacing them.